公开(公告)号：JPS615010A

公开(公告)日：1986-01-10

申请号：JP12379784

申请日：1984-06-18

Applicant: TOA EIYO LTD

Inventor： NARA TAKESHI ,  NISHINOMIYA YOUZOU ,  HAYASHI HISASHI ,  ISHIDA TADAO

IPC: A61K31/48 ,  A61K9/00 ,  A61K9/62 ,  A61K47/36

Abstract: PURPOSE:The titled pharmaceutical preparation capable of keeping blood concentration without damaging biological utility, obtained by coating nucleated particles of water-soluble additional matter of drug with a water-soluble gel high polymer film containing a hydrogenated ergot-alkaloid and a film consisting of an enteric base. CONSTITUTION:The surface of nucleated particles obtained by granulating a water-soluble additional matter of drug (e.g., lactose, or mannitol) is sprayed with a solution of a hydrogenated ergot-alkaloid (e.g., dihydroergotoxine) and a water-soluble gel high polymer such as hydroxypropyl cellulose, hydroxypropylmethyl cellylose, etc. in a blending ratio (weight ratio) of the former to the latter of 1:1-20, preferably 1:2-10 in an organic solvent, and it is dried. The prepared film is coated with a film of coating consisting of an enteric base (e.g., hydroxypropylmethyl cellulose phthalate) and/or ethyl cellulose, or coated in the opposite order, to give the aimed sustained release preparation.

公开(公告)号：JPS5993032A

公开(公告)日：1984-05-29

申请号：JP20026882

申请日：1982-11-17

Applicant: TOA EIYO LTD

Inventor： NARA TAKESHI ,  NISHINOMIYA YOUZOU ,  SATOU KENTAROU ,  KAMIKAMA KANEHITO

IPC: C08B37/16 ,  A61K47/40 ,  C07C67/00 ,  C07C201/00 ,  C07C201/02 ,  C07C201/16 ,  C07C203/02 ,  C07C203/04

Abstract: PURPOSE:The titled stable and easily handleable inclusion compound useful as a drug, capable of relieving irritation and preventing volatility, having high safety for tableting, molding, etc., obtained by including an isosorbidnitrate with cyclodextrin. CONSTITUTION:An isosorbidnitrate having a coronary blood vasodilating action, a dinitro ester or mononitro ester derivative of isosorbidnitrate widely used as a remedy and preventive for attack of angine pectoris in the form of a sublingual tablet, oral drug, sustained release drug, injection, etc., is dissolved or dispersed into a solvent containing preferably an equimolar amount of cyclodextrin and water, and the solvent is eliminated to give an isosorbidnitrate- cyclodextrin inclusion compound. alpha-, beta- and gamma-cyclodextrin, a cyclic oligosaccharide called cycloamylose, etc., comprising 6-8 constitutional units of D- glucopyranoses is used as the cyclodextrin.